Contract

Quality Assurance Document Control Specialist 1

Contract to Hire

Posted on 1/8/2026

Iovance Biotherapeutics

Iovance Biotherapeutics

501-1,000 employees

TIL-based T-cell therapies for solid tumors

No salary listed

Philadelphia, PA, USA

In Person

Category
QA & Testing (1)
Requirements
  • Bachelor’s degree in Life Sciences discipline is required.
  • Minimum of two (2) years of experience in document change management and archival or advanced degree without experience.
  • Minimum of two (2) years of experience in cGMP, FDA regulated industry is required.
  • Strong computer skills including MS Office Suite.
  • Must possess a high level of attention to details and have a strong quality mindset.
  • Must be organized.
  • Must be qualified, highly motivated, and a team player.
  • Ability to work effectively on multiple projects simultaneously with minimum supervision.
  • Strong interpersonal and communication skills.
Responsibilities
  • Responsible for issuance of unique identifier/lot number for identification and traceability of Patient and Non-Patient Manufacturing Lots.
  • Performs the issuance of Patient and Non-Patient batch records and required forms.
  • Generates and issues in-process labels for both Patient and Non-Patient Lots.
  • Supports the day-to-day need of Manufacturing, QC, and other departments at iCTC.
  • Must be proficient in Associate Level responsibilities to serve as a back-up, as needed. This includes logbooks and controlled copy issuance, and archival.
  • Independently manage, process, review, and approve the archival of documents in the Electronic Document Management System (eDMS).
  • Provide user assistance on eDMS
  • Responsible for problem solving related to job responsibilities.
  • Provides support for internal and regulatory audits and inspections as required.
  • Assists with maintaining Quality Assurance Document Control tracking tools for metric purposes.
  • Provides continuous feedback on improvements to Document Control processes.
  • Escalates issues or concerns to Area Management
  • Must adhere to Iovance Biotherapeutics’ core values, policies, procedures, and business ethics.
  • Perform miscellaneous duties required to complete the responsibilities stated in this Job Description (i.e. maintaining inventory of supplies and purchasing, maintaining the work area tidy, attend meetings, etc.).
  • Perform other duties assigned by the area management, which may or may not be associated with projects.
Desired Qualifications
  • Minimum of two (2) years of experience in document change management and archival or advanced degree without experience.
  • Minimum of two (2) years of experience in cGMP, FDA regulated industry is required.
  • Strong computer skills including MS Office Suite
  • Must possess a high level of attention to details and have a strong quality mindset
  • Must be organized
  • Must be qualified, highly motivated, and a team player
  • Ability to work effectively on multiple projects simultaneously with minimum supervision
  • Strong interpersonal and communication skills
Iovance Biotherapeutics

Iovance Biotherapeutics

View

Iovance Biotherapeutics develops cancer immunotherapies using Tumor Infiltrating Lymphocytes (TIL). It harvests T cells from a patient’s tumor, expands them in the lab, and infuses them back into the patient to attack solid tumors. The therapies are designed as single-treatment treatments without the need for ongoing maintenance. The company differentiates itself by focusing on TIL-based adoptive cell therapy with broad antigen targeting and dedicated cell therapy manufacturing capabilities, including the Iovance Cell Therapy Center (iCTC) to scale production. Its goal is to develop, manufacture, and commercialize proprietary TIL therapies and expand access to cell-based cancer treatments through partnerships and scaled production.

Company Size

501-1,000

Company Stage

IPO

Headquarters

New York City, New York

Founded

2007

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 revenue hit $71M, up 45% YoY, guiding $350-370M full-year.
  • Treatment centers expanded to 90+ US/Canada sites, targeting 110 by 2026-end.
  • Lifileucel shows 40% ORR in endometrial cancer, 50% in sarcomas, Fast Track for NSCLC.

What critics are saying

  • Q1 2026 Amtagvi revenue misses $70M estimate, shares drop 13%.
  • iCTC manufacturing bottlenecks prevent scaling to 110 centers by 2026-end.
  • Instil Bio's ITIL-306 gains FDA priority review, PDUFA Q4 2026, blocks endometrial entry.

What makes Iovance Biotherapeutics unique

  • Lifileucel delivers 19.7% 5-year OS rate in advanced melanoma post-checkpoint failure.
  • Amtagvi is first FDA-approved TIL therapy for solid tumors with single-dose protocol.
  • TIL therapy targets heterogeneous solid tumors using broad-spectrum patient lymphocytes.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Iovance Biotherapeutics who can refer or advise you

Benefits

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

4%

2 year growth

2%
Stock Titan
Mar 20th, 2026
Board member Wendy Yarno to retire from Iovance (NASDAQ: IOVA) after 2026 meeting.

Board member Wendy Yarno to retire from Iovance (NASDAQ: IOVA) after 2026 meeting. Filing Impact (Moderate) Filing Sentiment Rhea-AI filing summary. Iovance Biotherapeutics, Inc. reported that board member Wendy Yarno has notified the Board she will retire and will not stand for re-election at the company's annual meeting of stockholders, which is anticipated to be held in June 2026. Ms. Yarno will continue to serve as a director until the annual meeting. The company stated that her decision to retire is not due to any disagreement with Iovance regarding its operations, policies, or practices, and publicly thanked her for her service on the Board. 03/20/2026 - 05:00 PM Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): (Exact Name of Registrant as Specified in Charter) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Securities registered pursuant to Section 12(b) of the Act: On March 17, 2026, Wendy Yarno, a member of the Board of Directors (the "") of Iovance Biotherapeutics, Inc. (the ""), provided notice to the Board that she will retire from the Board and not be standing for re-election at the Company's annual meeting of stockholders (the "") currently anticipated to be held in June 2026. Ms. Yarno will serve out her current term as a director of the Company until the Annual Meeting. The decision to retire and not stand for re-election is not due to a disagreement between the Company and Ms. Yarno on any matter regarding the Company's operations, policies, or practices. The Company thanks Ms. Yarno for her service to the Board. Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Faq. What board change did Iovance Biotherapeutics (IOVA) disclose in this 8-K? Iovance Biotherapeutics disclosed that board member Wendy Yarno will retire and not stand for re-election at the upcoming annual meeting. She will remain on the Board until that meeting, and the company expressed appreciation for her service and contributions. When will Iovance Biotherapeutics (IOVA) director Wendy Yarno retire from the Board? Wendy Yarno will retire from the Iovance Biotherapeutics Board at the company's annual meeting of stockholders, currently anticipated for June 2026. She will continue serving as a director until that meeting, providing continuity during the transition period for the Board. Did Wendy Yarno's retirement from Iovance Biotherapeutics (IOVA) involve any disagreement with the company? The company stated that Wendy Yarno's decision to retire and not stand for re-election was not due to any disagreement regarding Iovance's operations, policies, or practices. This language signals an orderly governance transition rather than a dispute-driven departure. What role did Wendy Yarno hold at Iovance Biotherapeutics (IOVA) before announcing retirement? Wendy Yarno served as a member of the Board of Directors of Iovance Biotherapeutics. She notified the Board on March 17, 2026 that she will retire and not stand for re-election at the company's anticipated June 2026 annual stockholder meeting. How did Iovance Biotherapeutics (IOVA) characterize Wendy Yarno's retirement from the Board? Iovance Biotherapeutics indicated that Wendy Yarno's retirement is a personal decision, explicitly noting no disagreement over operations, policies, or practices. The company publicly thanked her for her service, framing the change as a normal board succession event. Filing exhibits & attachments. 3 documents

Yahoo Finance
Mar 7th, 2026
Iovance hits 52-week high as UBS doubles price target to $4

Iovance Biotherapeutics reached a new 52-week high of $5.34 on Friday before closing at $5.13, up 12.01 per cent, following UBS doubling its price target to $4 from $2, though maintaining a neutral rating. Wells Fargo reaffirmed its buy recommendation with a $14 price target. The biopharmaceutical company will participate in Barclays' 28th Annual Global Healthcare Conference on 11 March, where investors will watch for business updates. Iovance reported a 5 per cent wider net loss for 2024 at $390.98 million, whilst total revenues jumped 60.6 per cent to $263.5 million. Fourth-quarter net loss narrowed 8 per cent to $71.9 million, with revenues increasing 17.6 per cent to $86.7 million year-on-year.

Yahoo Finance
Mar 6th, 2026
UBS doubles price target on Iovance Biotherapeutics to $4 following strong Q4 revenue growth

UBS analyst David Dai raised the price target on Iovance Biotherapeutics from $2 to $4 whilst maintaining a Neutral rating. The upgrade follows fundamental improvements in fiscal Q4 2025, though the analyst noted that Amtagvi acceleration remains uncertain. Iovance reported quarterly revenue of $86.77 million, up 17.74% year-over-year and beating estimates by $5.76 million. Full-year product revenue reached $264 million, driven by a 112% increase in Amtagvi revenue. The drug, used for advanced melanoma treatment, saw accelerated uptake across academic and community treatment centres. The commercial-stage biopharmaceutical company develops cell therapies using autologous tumour-infiltrating lymphocytes for metastatic melanoma and other solid tumour cancers.

Yahoo Finance
Feb 28th, 2026
Iovance Biotherapeutics reports 61% annual revenue growth to $264M driven by Amtagvi success

Iovance Biotherapeutics reported 61% year-over-year revenue growth to $264 million for 2025, driven by its cancer treatment Amtagvi. Fourth-quarter product revenue reached $87 million, up 30% from the previous quarter. Amtagvi revenue increased 112% year-over-year. The biotech company achieved several regulatory milestones, including FDA Fast Track Designation for lifileucel in non-small cell lung cancer, supporting a projected 2027 launch. Clinical data showed a 50% confirmed response rate in advanced soft tissue sarcomas. The commercial-stage biopharmaceutical company develops cell therapies using autologous tumour infiltrating lymphocyte for metastatic melanoma and other solid tumour cancers. Management expressed confidence in the company's expanding pipeline and growing network of authorised treatment centres, with international market launches planned ahead.

Yahoo Finance
Feb 25th, 2026
Iovance grows Q4 revenue 30% to $87M, extends cash runway to Q3 2027

Iovance Biotherapeutics reported approximately 30% revenue growth in Q4 2025, with product revenue reaching $87 million. Full-year 2025 revenue totalled $264 million, a 61% increase year-over-year, driven primarily by its Amtagvi product, which saw 112% growth. The company's gross margin improved to 50% in Q4 from 43% in the previous quarter, following full internalisation of manufacturing operations. Iovance ended 2025 with $303 million in cash, extending its runway into Q3 2027. The FDA granted fast track designation for Lifileucel in non-small cell lung cancer. Clinical trials in advanced soft tissue sarcomas showed a 50% confirmed response rate. The company did not provide 2026 revenue guidance and faces challenges scaling community treatment centres beyond academic institutions.

INACTIVE